A.R.T. Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

A.R.T. Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-11,556	Closed	-$229K	–	1314
2019 Q3	$229K	Buy	11,556 +1,700	+17%	+$35.4K	0.01%	1149
2019 Q2	$208K	Buy	+9,856	New	+$206K	0.01%	1095
2018 Q2	–	Sell	-16,984	Closed	-$318K	–	1396
2018 Q1	$318K	Buy	+16,984	New	+$319K	0.01%	1110
2017 Q3	–	Sell	-16,100	Closed	-$287K	–	1334
2017 Q2	$287K	Buy	+16,100	New	+$255K	0.02%	1016
2016 Q2	–	Sell	-18,620	Closed	-$223K	–	1341
2016 Q1	$223K	Sell	18,620 -2,900	-13%	-$34.2K	0.01%	1134
2015 Q4	$306K	Buy	21,520 +1,800	+9%	+$23.8K	0.01%	1048
2015 Q3	$230K	Buy	+19,720	New	+$296K	0.01%	1131
2015 Q2	–	Sell	-20,621	Closed	-$308K	–	1458
2015 Q1	$308K	Buy	+20,621	New	+$276K	0.01%	1103

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

A.R.T. Advisors's AMPH Position: Q4 2019 in Review

A.R.T. Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2019, closing a stake of 11,556 shares — an estimated $229K sold.

A.R.T. Advisors first reported a position in AMPH in Q1 2015 and held it in 8 quarters. The position peaked at $318K in Q1 2018. 119 funds tracked by Wall St. Rank hold AMPH as of Q4 2019.

A.R.T. Advisors reported no remaining Amphastar Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 11,556 Amphastar Pharmaceuticals shares in Q4 2019, an estimated $229K.
A.R.T. Advisors first reported a position in Amphastar Pharmaceuticals in Q1 2015 and held it in 8 quarters.
A.R.T. Advisors's Amphastar Pharmaceuticals position peaked at $318K in Q1 2018.
119 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.